A structural comparative approach to identifying novel antimalarial inhibitors

Malaria continues to affect millions of people annually. With the rise of drug resistant strains, the need for alternative treatments has become increasingly urgent. Recently, PfUCHL3 was identified as an essential deubiquitinating enzyme. The increasing number of drug target structures being solved has increased the feasibility of utilizing a structural comparative approach to identifying novel inhibitors. Using AutoDock Vina, we recently screened the NCI library of about 320,000 compounds against the crystal structure of PfUCHL3. The top hits were subsequently screened against its human ortholog UCHL3 as to identify compounds that could specifically target the PfUCHL3 over its human counterpart. This method was used to identify small molecule inhibitors that can preferentially inhibit the parasitic enzyme. Several compounds were identified that demonstrated significant binding affinity preference for the malaria target over the human enzyme. Two of these compounds demonstrated ng/mL activity.

[1]  V. Quesada,et al.  Apicomplexan UCHL3 retains dual specificity for ubiquitin and Nedd8 throughout evolution , 2007, Cellular microbiology.

[2]  James R. Brown,et al.  Thousands of chemical starting points for antimalarial lead identification , 2010, Nature.

[3]  Tudor I. Oprea,et al.  Integrating virtual screening in lead discovery. , 2004, Current opinion in chemical biology.

[4]  Christoph A Sotriffer,et al.  Addressing Protein Flexibility and Ligand Selectivity by “in situ Cross‐Docking” , 2006, ChemMedChem.

[5]  Ettore Novellino,et al.  Pursuing aldose reductase inhibitors through in situ cross-docking and similarity-based virtual screening. , 2009, Journal of medicinal chemistry.

[6]  S. Knapp,et al.  Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases. , 2006, The Biochemical journal.

[7]  K. Chibale,et al.  Quinoline antimalarials containing a dibemethin group are active against chloroquinone-resistant Plasmodium falciparum and inhibit chloroquine transport via the P. falciparum chloroquine-resistance transporter (PfCRT). , 2011, Journal of medicinal chemistry.

[8]  David A. Fidock,et al.  Drug discovery: Priming the antimalarial pipeline , 2010, Nature.

[9]  S. Hay,et al.  The global distribution of clinical episodes of Plasmodium falciparum malaria , 2005, Nature.

[10]  Tamitza Toroyan,et al.  Global status report on road safety , 2009, Injury Prevention.

[11]  Brian K. Shoichet,et al.  ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..

[12]  Michael K. Gilson,et al.  Screening Drug-Like Compounds by Docking to Homology Models: A Systematic Study , 2006, J. Chem. Inf. Model..

[13]  Campbell McInnes,et al.  Virtual screening strategies in drug discovery. , 2007, Current opinion in chemical biology.

[14]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[15]  Adrian H Elcock,et al.  Progress toward virtual screening for drug side effects , 2002, Proteins.

[16]  H. Ploegh,et al.  Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. , 2002, Chemistry & biology.

[17]  R. Piper,et al.  Parasite lactate dehydrogenase as an assay for Plasmodium falciparum drug sensitivity. , 1993, The American journal of tropical medicine and hygiene.

[18]  H. Ploegh,et al.  Ubiquitination, Ubiquitin-like Modifiers, and Deubiquitination in Viral Infection , 2009, Cell Host & Microbe.

[19]  K. Kirk,et al.  Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance , 2005, Molecular microbiology.

[20]  J. Wootton,et al.  Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. , 2000, Molecular cell.

[21]  Christoph A Sotriffer,et al.  "In situ cross-docking" to simultaneously address multiple targets. , 2005, Journal of medicinal chemistry.

[22]  Michael K. Gilson,et al.  Comparing Ligand Interactions with Multiple Receptors via Serial Docking , 2004, J. Chem. Inf. Model..

[23]  Didier Rognan,et al.  In silico-guided target identification of a scaffold-focused library: 1,3,5-triazepan-2,6-diones as novel phospholipase A2 inhibitors. , 2006, Journal of medicinal chemistry.

[24]  Max W. Chang,et al.  Analysis of HIV Wild-Type and Mutant Structures via in Silico Docking against Diverse Ligand Libraries , 2007, J. Chem. Inf. Model..

[25]  David Toth,et al.  Using Supercomputing to Conduct Virtual Screen as Part of the Drug Discovery Process in a Medicinal Chemistry Course , 2012 .

[26]  W. Trager,et al.  Human malaria parasites in continuous culture. , 1976, Science.

[27]  D. Fidock,et al.  In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. , 2008, International journal for parasitology.

[28]  X. Su,et al.  A molecular marker for chloroquine-resistant falciparum malaria. , 2001, The New England journal of medicine.

[29]  Bradley I. Coleman,et al.  Characterization and Structural Studies of the Plasmodium falciparum Ubiquitin and Nedd8 Hydrolase UCHL3 , 2009, The Journal of Biological Chemistry.

[30]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[31]  G A Petsko,et al.  Chemistry and biology. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[32]  W. Denny,et al.  Phosphoinositide-3-kinase (PI3K) inhibitors: identification of new scaffolds using virtual screening. , 2009, Bioorganic & medicinal chemistry letters.

[33]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.